CoChat

Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo

Open access
Montes de Oca, Rocio, Alavi, Alireza S., Vitali, Nick, Bhattacharya, Sabyasachi, Blackwell, Christina, Patel, Krupa, Seestaller-Wehr, Laura, Kaczynski, Heather, Shi, Hong, Dobrzynski, Eric, Obert, Leslie, Tsvetkov, Lyuben, Cooper, David C., Jackson, Heather, Bojczuk, Paul, Forveille, Sabrina, Kepp, Oliver, Sauvat, Allan, Kroemer, Guido, Creighton-Gutteridge, Mark, Yang, Jingsong, Hopson, Chris, Yanamandra, Niranjan, Shelton, Christopher, Mayes, Patrick, Opalinska, Joanna, Barnette, Mary, Srinivasan, Roopa, Smothers, James, Hoos, Axel · 2021 · Molecular Cancer Therapeutics
Cited by 116

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

B-cell maturation antigen (BCMA) is an attractive therapeutic target highly expressed on differentiated plasma cells in multiple myeloma and other B-cell malignancies. GSK2857916 (belantamab mafodotin, BLENREP) is a BCMA-targeting antibody–drug conjugate approved for the treatment of relapsed/refractory multiple myeloma. We report that GSK2857916 induces immunogenic cell death in BCMA-expressing cancer cells and promotes dendritic cell activation in vitro and in vivo. GSK2857916 treatment enhances intratumor immune cell infiltration and activation, delays tumor growth, and promotes durable complete regressions in immune-competent mice bearing EL4 lymphoma tumors expressing human BCMA (EL4-hBCMA). Responding mice are immune to rechallenge with EL4 parental and EL4-hBCMA cells, suggesting engagement of an adaptive immune response, immunologic memory, and tumor antigen spreading, which are abrogated upon depletion of endogenous CD8+ T cells. Combinations with OX40/OX86, an immune agonist antibody, significantly enhance antitumor activity and increase durable complete responses, providing a strong rationale for clinical evaluation of GSK2857916 combinations with immunotherapies targeting adaptive immune responses, including T-cell–directed checkpoint modulators.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-21-0035

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 116

Metadata

Authors
Montes de Oca, R., Alavi, A. S., Vitali, N., Bhattacharya, S., Blackwell, C., Patel, K., Seestaller-Wehr, L., Kaczynski, H., Shi, H., Dobrzynski, E., Obert, L., Tsvetkov, L., Cooper, D. C., Jackson, H., Bojczuk, P., Forveille, S., Kepp, O., Sauvat, A., Kroemer, G., Creighton-Gutteridge, M., Yang, J., Hopson, C., Yanamandra, N., Shelton, C., Mayes, P., Opalinska, J., Barnette, M., Srinivasan, R., Smothers, J., & Hoos, A.
Venue
Molecular Cancer Therapeutics
Published
2021-07-12
Volume
20
Issue
10
Pages
1941-1955
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W3177941998
Cited by
116
References
14
FWCI
5.43
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo. https://app.cochat.ai/papers/10.1158/1535-7163.mct-21-0035
The paper
Montes de Oca, R., Alavi, A. S., Vitali, N., Bhattacharya, S., Blackwell, C., Patel, K., Seestaller-Wehr, L., Kaczynski, H., Shi, H., Dobrzynski, E., Obert, L., Tsvetkov, L., Cooper, D. C., Jackson, H., Bojczuk, P., Forveille, S., Kepp, O., Sauvat, A., Kroemer, G., . . . Hoos, A. (2021). Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-21-0035

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.